ES2033574B1 - Un metodo para la preparacion de derivados de furo(3,4-c) piridina en una forma no racemica. - Google Patents

Un metodo para la preparacion de derivados de furo(3,4-c) piridina en una forma no racemica.

Info

Publication number
ES2033574B1
ES2033574B1 ES9101157A ES9101157A ES2033574B1 ES 2033574 B1 ES2033574 B1 ES 2033574B1 ES 9101157 A ES9101157 A ES 9101157A ES 9101157 A ES9101157 A ES 9101157A ES 2033574 B1 ES2033574 B1 ES 2033574B1
Authority
ES
Spain
Prior art keywords
derivatives
piridine
furo
preparation
racemic form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES9101157A
Other languages
English (en)
Other versions
ES2033574A1 (es
Inventor
Charles R Eck
Paul C Shrens
Rae Marie Saltzstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS filed Critical Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Publication of ES2033574A1 publication Critical patent/ES2033574A1/es
Application granted granted Critical
Publication of ES2033574B1 publication Critical patent/ES2033574B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/182—Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
    • C12P41/004—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of alcohol- or thiol groups in the enantiomers or the inverse reaction

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

UN METODO PARA LA PREPARACION DE DERIVADOS DE FURO[3,4-C]PIRIDINA EN UNA FORMA NO RACEMICA, DE FORMULA FORMULA Y SUS SALES FARMACEUTICAMENTE ACEPTABLES, EN DONDE R3,R''3,R4 Y R6 REPRESENTAN DIVERSOS SUBSTITUYENTES, COMPRENDIENDO DICHO METODO RESOLVER UNA MEZCLA RACEMICA DE UNO DE LOS COMPUESTOS DE LAS FORMULAS (2) Y (3) EN DONDE R3,R''3,R4 Y R6 SON COMO SE HAN DEFINIDO ANTERIORMENTE Y R7 REPRESENTA UN GRUPO ACILO DE HASTA C18, SOMETIENDO EL COMPUESTO SELECCIONADO A LA ACCION DE UNA ESTERASA CAPAZ DE HIDROLIZAR LA FORMA ENANTIOMERA (+) O LA FORMA ENANTIOMERA (-) DEL COMPUESTO SELECCIONADO Y SEPARANDO DESPUES LOS COMPUESTOS SIN HIDROLIZAR E HIDROLIZADO. LOS DERIVADOS PREPARADOS TIENEN ACTIVIDADES TERAPEUTICAS DIVERSAS.
ES9101157A 1990-05-14 1991-05-13 Un metodo para la preparacion de derivados de furo(3,4-c) piridina en una forma no racemica. Expired - Fee Related ES2033574B1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/523,238 US5130252A (en) 1990-05-14 1990-05-14 Resolution of furopyridine enantiomers and synthetic precursors thereof

Publications (2)

Publication Number Publication Date
ES2033574A1 ES2033574A1 (es) 1993-03-16
ES2033574B1 true ES2033574B1 (es) 1994-02-01

Family

ID=24084213

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9101157A Expired - Fee Related ES2033574B1 (es) 1990-05-14 1991-05-13 Un metodo para la preparacion de derivados de furo(3,4-c) piridina en una forma no racemica.

Country Status (32)

Country Link
US (1) US5130252A (es)
JP (1) JPH05117277A (es)
KR (1) KR910020015A (es)
AR (1) AR247762A1 (es)
AT (1) AT400445B (es)
AU (1) AU642368B2 (es)
BE (1) BE1007016A3 (es)
CA (1) CA2042421C (es)
CH (1) CH682488A5 (es)
DE (1) DE4115681C2 (es)
DK (1) DK88991A (es)
DZ (1) DZ1499A1 (es)
ES (1) ES2033574B1 (es)
FI (1) FI97807C (es)
FR (1) FR2661919B1 (es)
GB (1) GB2244056B (es)
GR (1) GR1001593B (es)
HK (1) HK131993A (es)
IE (1) IE65891B1 (es)
IT (1) IT1248743B (es)
LU (1) LU87935A1 (es)
MA (1) MA22154A1 (es)
MY (1) MY107567A (es)
NL (1) NL194615C (es)
NO (1) NO180308C (es)
NZ (1) NZ238009A (es)
OA (1) OA09352A (es)
PT (1) PT97657B (es)
SE (1) SE510808C2 (es)
TN (1) TNSN91035A1 (es)
TW (1) TW226998B (es)
ZA (1) ZA913461B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0221494D0 (en) * 2002-09-16 2002-10-23 Generics Uk Ltd Novel processes for the preparation of 1.3-dihydro-6-methylfuro (3,4-c) pyndin derivatives
US20110251396A1 (en) * 2003-07-17 2011-10-13 Gilead Sciences, Inc. Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
US20060089374A1 (en) * 2003-07-17 2006-04-27 Glenn Cornett Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
WO2005009446A1 (en) * 2003-07-17 2005-02-03 Cotherix, Inc. Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome
GB2423927A (en) * 2003-08-29 2006-09-13 Cotherix Inc Combination Of Cicletanine And An Oral Antidiabetic And/Or Blood Lipid-Lowering Agent For Treating Diabetes And Metabolic Syndrome
US20060154959A1 (en) * 2005-01-13 2006-07-13 Navitas Pharma Combination therapies of cicletanine and carvedilol
US7375112B2 (en) * 2005-01-05 2008-05-20 Medicure International Inc. Compounds and methods for regulating triglyceride levels
US20070141174A1 (en) * 2005-01-13 2007-06-21 Navitas Pharma, Inc. Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension
US20080096915A1 (en) * 2005-01-13 2008-04-24 Greenberg Traurig LLP Compositions for the treatment of metabolic disorders
US20070105817A1 (en) * 2005-11-09 2007-05-10 Jim Page Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension
CA2674367A1 (en) * 2007-01-03 2008-07-17 Glenn V. Cornett Cicletanine and pkc inhibitors in the treatment of pulmonary and cardiac disorders
EP2498605B1 (en) * 2009-10-29 2014-08-27 Merck Sharp & Dohme Corp. Diuretics

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN156817B (es) * 1981-02-10 1985-11-09 Scras
US4985365A (en) * 1981-11-28 1991-01-15 Sumitomo Chemical Company, Ltd. Process for producing optically active benzyl alcohol compound
DE3378834D1 (en) * 1982-08-13 1989-02-09 Kanegafuchi Chemical Ind Process for production of optically active oxazolidinone derivative
IN160104B (es) * 1983-04-05 1987-06-27 Scras
JPS59216590A (ja) * 1983-05-24 1984-12-06 Ube Ind Ltd 光学活性フエニルプロパルギルアルコ−ル誘導体の製法
GB8327817D0 (en) * 1983-10-18 1983-11-16 Scras 4-halo-furo-(3 4-c)-pyridine derivatives
GB8330517D0 (en) * 1983-11-16 1983-12-21 Scras 6-vinyl-furo-(3,4-c)pyridine derivatives
GB8330658D0 (en) * 1983-11-17 1983-12-29 Scras 7-carboxymethoxy-furo-(3,4-c)-pyridine derivatives
GB8402740D0 (en) * 1984-02-02 1984-03-07 Scras Furo-(3 4-c)-pyridine derivatives
JPS60224494A (ja) * 1984-04-24 1985-11-08 Nissan Chem Ind Ltd α−メチルベンジルアルコ−ル類の光学分割法
GB8414559D0 (en) * 1984-06-07 1984-07-11 Scras Pyridine derivatives
GB8427218D0 (en) * 1984-10-27 1984-12-05 Scras Pyridine derivatives
JPS61289899A (ja) * 1985-06-18 1986-12-19 Kanegafuchi Chem Ind Co Ltd 光学活性２−ハロ−１−フエニルエタノ−ルおよびそのエステルの製造法
US4916074A (en) * 1986-10-30 1990-04-10 Chisso Corporation Process for producing optically active compounds
JP2691986B2 (ja) * 1987-08-28 1997-12-17 チッソ株式会社 ピリジン骨格を有する光学活性化合物の製造法
DE3737335A1 (de) * 1987-11-04 1989-05-18 Basf Ag Verfahren zur herstellung eines biokatalysators und dessen verwendung zur razematspaltung
GB8808001D0 (en) * 1988-04-06 1988-05-05 Scras Stereospecific preparative process for furol(3,4-c)pyridine derivatives
DE3990349T1 (de) * 1988-04-06 1990-04-26 Scras Stereospezifisches verfahren zur herstellung von enantiomeren von furo(3,4-c)pyridin, so erhaltene verbindungen und therapeutische zusammensetzungen auf basis dieser verbindungen
NL8801311A (nl) * 1988-05-20 1989-12-18 Stamicarbon Fenylglycidaatstereoisomeren, omzettingsprodukten daarvan met 2-nitrothiofenol en de bereiding van diltiazem.
GB8907480D0 (en) * 1989-04-03 1989-05-17 Scaras Societe De Conseils De Separation of insomers of furo(3,4-c)pyridine derivatives
GB8917168D0 (en) * 1989-07-27 1989-09-13 Scras Asymmetric synthesis of furo(3,4-c)pyridine derivatives

Also Published As

Publication number Publication date
ITMI911255A1 (it) 1992-11-08
SE510808C2 (sv) 1999-06-28
ES2033574A1 (es) 1993-03-16
GB9109810D0 (en) 1991-06-26
MY107567A (en) 1996-04-30
FI97807C (fi) 1997-02-25
FR2661919B1 (fr) 1994-12-30
ITMI911255A0 (it) 1991-05-08
NO180308B (no) 1996-12-16
FI912315A0 (fi) 1991-05-13
GB2244056A (en) 1991-11-20
KR910020015A (ko) 1991-12-19
JPH05117277A (ja) 1993-05-14
US5130252A (en) 1992-07-14
NZ238009A (en) 1992-11-25
CA2042421A1 (en) 1991-11-15
ZA913461B (en) 1992-02-26
NL9100749A (nl) 1991-12-02
DK88991D0 (da) 1991-05-13
FI912315A (fi) 1991-11-15
MA22154A1 (fr) 1991-12-31
ATA98291A (de) 1995-05-15
PT97657A (pt) 1992-02-28
DZ1499A1 (fr) 2004-09-13
LU87935A1 (fr) 1992-03-03
FR2661919A1 (fr) 1991-11-15
DE4115681A1 (de) 1991-11-21
GR1001593B (el) 1993-03-31
BE1007016A3 (fr) 1995-02-21
CH682488A5 (fr) 1993-09-30
TW226998B (es) 1994-07-21
DE4115681C2 (de) 2003-10-30
SE9101431L (sv) 1991-11-15
AU7620091A (en) 1991-11-14
AU642368B2 (en) 1993-10-14
GR910100180A (en) 1992-07-30
PT97657B (pt) 1998-09-30
IE65891B1 (en) 1995-11-29
NO180308C (no) 1997-03-26
DK88991A (da) 1991-11-15
HK131993A (en) 1993-12-10
SE9101431D0 (sv) 1991-05-13
IE911628A1 (en) 1991-11-20
NL194615C (nl) 2002-09-03
GB2244056B (en) 1993-08-11
IT1248743B (it) 1995-01-26
NL194615B (nl) 2002-05-01
OA09352A (fr) 1992-09-15
TNSN91035A1 (fr) 1992-10-25
NO911852L (no) 1991-11-15
CA2042421C (en) 2000-08-22
FI97807B (fi) 1996-11-15
AR247762A1 (es) 1995-03-31
AT400445B (de) 1995-12-27
NO911852D0 (no) 1991-05-13

Similar Documents

Publication Publication Date Title
ES2033574B1 (es) Un metodo para la preparacion de derivados de furo(3,4-c) piridina en una forma no racemica.
FI972967A (fi) Imidatso(4,5-c)kinoliiniamiineja
ES2137932T3 (es) Procedimiento para la preparacion de analogos de camptotecina solubles en agua, asi como los compuestos 10-hidroxi-11-alcoxi-6-camptotecina.
ATE146473T1 (de) Pyrazolopyridinverbindungen und verfahren zu ihrer herstellung
GB1467138A (en) Acetylene derivatives of amino acids
UA27901C2 (uk) Похідні 7-(2-аміноетил)бензотіазолону, що проявляють агоністичну активність по відношенню до бета2-адренорецепторів, фармацевтична композиція, спосіб їх отримання та проміжні сполуки
DK390587D0 (da) 7-oeoe3-aminomethyl-3-alkylaa-1-pyrrolidinylaa-quino lin-carboxylsyre
NO940523D0 (no) Nye pyrazin-derivater
ATE74346T1 (de) Alkensaeurederivate.
SE8007845L (sv) Terapeutiska kompositioner, innehallande nya indol-(2,3-a)kinolizidiner som aktiv betsandsdel i blandning med ett for administreringsformen i fraga lempat, i och for sig kent bindemedel
GB2005259A (en) Hexahydropyrrolo indole derivatives
ATE25679T1 (de) Isochinolinderivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung.
BR8400549A (pt) Derivados e sais inertes de hidroxido de aminopiridinios e processos de preparacao;e composicao farmaceutica
PE20040916A1 (es) Diamidas de acido pirimidin-4,6-dicarboxilico como inhibidores selectivos de mmp-13
DK0628042T3 (da) Serotoninerge ergolinderivater
ES2087474T3 (es) Derivados de aril-3 oxazolidinona, procedimiento de preparacion y aplicacion terapeutica de los mismos.
SE7902915L (sv) 4-oxo-4h-pyrido(1,2-a)pyrimidin-3-n-(1h-tetrazol-5-yl) karboxamidderivat och deras anvendning sasom inhibitorer av allergiska reaktioner
FI97883B (fi) Menetelmä lääkeaineena käyttökelpoisen glyserolijohdannaisen valmistamiseksi
MX9302711A (es) Preparacion de base.
SE8601799L (sv) (-)-1beta-etyl-1alfa-hydroximetyl-1,2,3,4,6,7,12,12balfa-iktahydroindolo/2,3-a/-kinolizin, forfarande for dess framstellning och farmaceutiska beredningar innehallande densamma
ES2046528T3 (es) Derivados heterotetraciclicos de lactamas, proceso para su preparacion y composiciones farmaceuticas a base de los mismos.
DE3884508D1 (de) Cystein-derivate mit expectorans-wirkung.
ES2040783T3 (es) Procedimiento para preparar antagonistas de leucotrienos.
SE8204792L (sv) N-metyl-d-glukaminsalt av 3,4-dihydro-5-metyl-6-(2-metyl-propyl)-4-oxotieno(2,3-d)pyrimidin-2-karboxylsyra och farmaceutisk komposition innehallande detta salt
ES8800922A1 (es) Procedimiento para la obtencion del antipoda levogiro y dextrogiro del racemato del acido 5-cloro-6-(3-clorobencenosulfonil)-1,3-benzodioxol-2-carboxilico

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20041102